InvestorsHub Logo
Followers 22
Posts 3415
Boards Moderated 0
Alias Born 04/01/2000

Re: big_haze post# 805

Friday, 07/05/2019 7:02:52 AM

Friday, July 05, 2019 7:02:52 AM

Post# of 5359
big haze, thanks for your DD regarding AXIM. I like what AXIM® Biotech CEO John W. Huemoeller II has to say:

“As a mid-stage biotech company, we found it strategic and necessary to partner with larger organizations who are experts in their respective fields in order to bring AXIM products to a much larger worldwide audience. This clinical trial registration through Impression is a tangible example of this methodology working,” said AXIM® Biotech CEO John W. Huemoeller II. “Navigating the various regulatory agencies around the world in order to conduct clinical research on our products is both time-consuming and costly. Partnering with companies like Impression allows for AXIM’s products to be researched on a much faster and more cost-effective basis. We are extremely excited to reveal what we hope to be successful results that only further AXIM’s value-proposition as a leader in pharmaceutical quality cannabinoid-based products.”

https://www.globenewswire.com/news-release/2019/06/25/1873831/0/en/AXIM-Biotechnologies-Signs-Supply-Agreement-to-Register-Cannabinoid-Oral-Care-Products-in-Clinical-Trials-for-Gingivitis-and-Gum-Disease.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXIM News